MedTrace Logo

Sustained onabotulinumtoxinA Therapeutic Benefits in Patients With Chronic Migraine

NCT03606356 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2018-07-30

No results posted yet for this study

Summary

To assess whether there is a sustained benefit and good safety with repeated onabotulinumtoxinA sessions in chronic migraine over more than three years of treatment.

We prospectively enrolled 65 chronic migraine patients, who were classified as responders after three sessions of onabotulinumtoxin A and were eligible to further continue treatment.

Conditions

  • Migraine Disorders

Interventions

DRUG

Onabotulinum toxin A

Cranial Subcutaneous Injections

Sponsors & Collaborators

  • Corfu Headache Clinic

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-01
Primary Completion
2018-04-01
Completion
2018-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03606356 on ClinicalTrials.gov